October 2014 Newsletter

October 7, 2014:

14,000 Register in Advance for AAO Meeting; Attendees Will Find Improved Venue in Chicago

The conference will be held October 18 to 21 at McCormick Place.

October 7, 2014:

Market Scope’s List of Must-See Sessions at the AAO Meeting

October 7, 2014:

AAO Meeting Preview: What Awaits Attendees

October 7, 2014:

AAO Meeting Preview: Retinal Pharmaceuticals

October 7, 2014:

AAO Meeting Preview: Cataract Surgical Devices

October 7, 2014:

AAO Meeting Preview: Refractive Surgical Devices

October 7, 2014:

AAO Meeting Preview: Diagnostic Devices

October 7, 2014:

AAO Meeting Preview: Glaucoma and Dry Eye

October 7, 2014:

AAO Meeting Preview: Top Company Leaders to Speak at Ophthalmology Innovation Summit

October 7, 2014:

Come by Our Booth at the AAO Meeting

October 7, 2014:

US Refractive Procedure Volumes Fall for the Seventh Consecutive Quarter

Q2-2014 procedures declined 1.4 percent year over year and 2.9 percent compared with Q1-2014.

October 7, 2014:

US IOL Procedures Increase 5 Percent in Second Quarter

Responses to our Q2-2014 survey indicate a recovery from the weather-impacted first quarter.

October 7, 2014:

Alimera Sciences Plans to Price Iluvien at $8,000 to $9,000

In a conference call, Alimera Sciences discussed its plans to market its DME treatment following FDA regulatory approval.

October 7, 2014:

Ozurdex Label Expanded for DME Population

The implant was originally approved in June as a treatment for DME in adult patients who have an artificial lens implant or who are scheduled for cataract surgery.

October 7, 2014:

FDA Panel to Review AcrySof IQ ReSTOR Multifocal Toric Lens

The advisory meeting is set for November 14 in Gaithersburg, MD.

October 7, 2014:

Allergan’s Talks with Salix Stall Again

As the drugmaker’s battle with Valeant continues, the focus now turns to a special meeting of shareholders in December.

October 7, 2014:

US Treasury Announces Rule Changes to Curb Corporate Inversions

Once such merger has already been scuttled: Salix Pharmaceuticals’ acquisition of Italy’s Cosmo Pharmaceuticals.

October 7, 2014:

Mazzo Indicted on Charges of Insider Trading

The former head of Advanced Medical Optics is under fire in a case involving a former major league baseball player.

October 7, 2014:

Ocular Hypotensive Product Candidate Vesneo Achieves Positive Phase III Results for B+L, Nicox

In its two Phase III clinical trials, the treatment met the primary endpoint of non-inferiority with once-daily dosing versus twice-daily dosing of timolol maleate.

October 7, 2014:

October 2014 News Briefs

Social media